ClinicaliQ Trial Snapshot
- A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis — Recruiting • Phase II • Oncology • NCT06055959.
- What is being tested: Subcutaneous zilucoplan, a complement C5 inhibitor, is being evaluated for its pharmacokinetics, safety, tolerability, immunogenicity and clinical activity in pediatric patients with generalized myasthenia gravis (gMG).
- Patient eligibility overview: The study recruits pediatric participants diagnosed with generalized myasthenia gravis; specific age ranges and disease severity criteria would be defined in the full protocol to ensure appropriate patient selection.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
Eligibility Snapshot
- : United States of America (USA) specific inclusion criterion: - Participant must be 12 to
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.